The Prostate Cancer Program of the UCSF Helen Diller Family Comprehensive Cancer Center is committed to offering the best treatment options tailored to the individual needs of our patients, innovative research programs, and an outstanding educational program that trains the future leaders in the field. We are one of the most productive and innovative prostate cancer programs in the nation having pioneered treatment options ranging from active surveillance for early stage disease to the development of therapies for advanced prostate cancer. Our thriving multidisciplinary group of physicians and investigators is committed to leading advancements in the diagnosis, treatment and prevention of prostate disease.
The Johns Hopkins Prostate Cancer Team is recognized for its leadership in diagnosing, treating, and conducting groundbreaking research for prostate cancer. The radical retropubic prostatectomy was developed by Dr. Patrick C. Walsh at the Brady Institute. The first prostate cancer gene was identified at John Hopkins. The Partin Tables and Han Tables, widely used to predict prostate cancer’s stage and likelihood of recurrence, were developed by our team; and we house the only urology robotics laboratory in the country. Innovations like these have led to the Brady’s designation by U.S. News and World Report as the #1 urology department in the nation, for 21 consecutive years. Today, the Johns Hopkins Prostate Cancer Team continues to break new ground by providing a multi-disciplinary approach to treating prostate cancer. This involves close collaboration between a urologist, oncologist, and a radiation oncologist to deliver the best science, the most customized treatment and the best outcome for each individual patient.
UCLA’s Prostate Cancer Treatment and Research Program (PCTRP) is one of the leading prostate cancer programs in the nation. Our success is manifest in the development of new engineering solutions to improve the accuracy of prostate cancer diagnosis, novel imaging agents to stage prostate cancer, the first quality of life instruments to improve prostate cancer care, and the discovery and approval of novel drugs such as enzalutamide to treat advanced disease. The National Cancer Institute designated the UCLA PCTRP as a Specialized Program of Research Excellence (SPORE) in 2002, recognizing it nationwide as an institution tapped to improve prevention, detection and treatment of the disease.
The Prostate Cancer Program—led by Northwestern’s nationally ranked Department of Urology—is a comprehensive program providing exceptional patient care and high-impact research studies. Research efforts center on: investigating the cellular and molecular biology of prostate cancer; investigating epidemiology, prevention, early detection, prognosis, and risk factors; and conducting innovative prostate cancer therapeutics, quality of life, and clinical outcomes research. Northwestern’s Prostate Cancer Program coordinates and encourages collaborative translational research projects in the area of prostate cancer at Northwestern University.
MD Anderson Cancer Center in Houston is one of the world’s most respected centers devoted to cancer patient care, research, education, and prevention. The Prostate Cancer Program reflects MD Anderson’s pioneering multidisciplinary approach, with successful treatment for early-stage prostate cancer and innovative therapies for advanced disease. Dedicated faculty from urology, medical oncology, radiation oncology, and related disciplines collaborate to ensure each patient receives optimum care. We advocate the bench-to-bedside approach, which ensures knowledge gained in the laboratory is rapidly translated to the patient in the clinic. What we learn from patient care is then returned to the laboratory to develop therapies for the control of prostate cancer.
Recognized as an international leader in the diagnosis and treatment of prostate cancer, Memorial Sloan-Kettering provides lifesaving care to thousands of patients drawn to the Center by its exceptional physicians and scientists, whose extensive knowledge of the disease is matched only by the expertise gained in treating it every day. Our team of thirty board certified prostate cancer specialists work collaboratively to establish therapeutic goals for each patient at the time of diagnosis, and continue to redefine them as the disease unfolds and the patient’s needs evolve. As a result, each goal represents a clinically significant milestone that patients may experience during the course of treatment.